EGFR and non-small cell lung carcinoma: In the OPTIMAL, CTONG-0802 trial, patients with histologically confirmed stage IIIB or stage IV NSCLC (according to the 6th edition of TNM) and an activating mutation of EGFR (exon 19 deletion or exon 21 L858R point mutation) were randomly assigned to receive oral erlotinib or up to four cycles of gemcitabine plus carboplatin.